4-methyl-2-furanylmethylamine | 120073-83-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-methyl-2-furanylmethylamine
• 英文别名: 4-methyl-2-furanmethanamine；(4-methylfuran-2-yl)methanamine
• CAS: 120073-83-8
• 化学式: C₆H₉NO
• mdl: MFCD15145793
• 分子量: 111.144
• InChiKey: HMHSVQXZBMKUMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  39.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-methyl-2-furanylmethylamine 在 盐酸 、 sodium periodate 、 四丁基氟化铵 、 碳酸氢钠 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 2.0h， 生成 (1R,2S,4R,5R,8R,9S,11R)-9-formyl-2-[[(2R,6S,7R)-6-hydroxy-2-methyl-4-[(4-methylfuran-2-yl)methyl]-1,4-oxazepan-7-yl]oxymethyl]-5-methyl-13-propan-2-yltetracyclo[7.4.0.02,11.04,8]tridec-12-ene-1-carboxylic acid
  参考文献：
  名称：

  Sordarin Oxazepine Derivatives as Potent Antifungal Agents

  摘要：

  The synthesis and biological activity of sordarin oxazepine derivatives are described. The key step features a regioselective oxidation of an unprotected triol followed by double reductive amination to afford the ring-closed products. The spectrum of antifungal activity for these novel derivatives includes coverage of Candida albicans, Candida glabrata, and Cryptococcus neoformans. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00529-2
• 作为产物：
  描述：

  (NE)-N-[(4-methylfuran-2-yl)methylidene]hydroxylamine 生成 4-methyl-2-furanylmethylamine
  参考文献：
  名称：

  JANSSENS, FRANS E.;TORREMANS, JOSEPH L. G.;DIELS, GASTON S. M.

  摘要：

  DOI：

文献信息

• [EN] ORAL COMPLEMENT FACTOR D INHIBITORS<br/>[FR] INHIBITEURS DE FACTEUR D DU COMPLÉMENT ORAL
  申请人：BIOCRYST PHARM INC

  公开号：WO2021072156A1

  公开（公告）日：2021-04-15

  Disclosed are compounds of formula (I)-(IV), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

  揭示了式(I)-(IV)的化合物及其药用可接受的盐，这些化合物是补体系统的抑制剂。还提供了包含这种化合物的药物组合物，以及使用这些化合物和组合物治疗或预防由异常补体系统活动特征的疾病或状况的方法。
• N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives useful
  申请人：Janssen Pharmaceutical N.V.

  公开号：US04897401A1

  公开（公告）日：1990-01-30

  Novel N-(4-piperidinyl)bicyclic condensed 2-imidazolamine derivatives and their pharmaceutically acceptable acid addition salts having anti-histaminic properties, compositions containing the same, and methods of treating allergic diseases in warm-blooded animals.

  新型N-(4-哌啶基)双环缩合2-咪唑胺衍生物及其药用可接受的酸盐，具有抗组胺作用，含有这些物质的组合物，以及治疗温血动物过敏病的方法。
• INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA
  申请人：Northwestern University

  公开号：US20180098952A1

  公开（公告）日：2018-04-12

  Disclosed are methods, compounds, and compositions for treating infection by an Apicomplexan parasite that include administering a compound that selectively inactivates ornithine aminotransferase of the Apicomplexan parasite. Specifically, the methods, compounds, compounds may be utilized for treating infection by Toxoplasma gondii and toxoplasmosis and for treating infection by Plasmodium falciparum and malaria. The compounds disclosed herein are observed to selectively inactivate Toxoplasma gondii ornithine aminotransferase (TgOAT) relative to human OAT and relative to human γ-aminobutyric aminotransferase (GABA-AT).

  揭示了一种治疗具有选择性灭活裂殖孢子虫的鸟氨基转移酶的化合物、方法和组合物。具体来说，这些方法、化合物可用于治疗弓形虫和弓形虫病感染，以及治疗疟原虫和疟疾感染。本文披露的化合物被观察到相对于人类鸟氨基转移酶和人类γ-氨基丁酸氨基转移酶（GABA-AT）具有选择性地灭活弓形虫鸟氨基转移酶（TgOAT）。
• Pharmacologically active N-(4-piperidinyl) bicyclic condensed
  申请人：Janssen Pharmaceutica N.V.

  公开号：US05006527A1

  公开（公告）日：1991-04-09

  Novel N-(4-piperindyl)bicyclic condensed 2-imidazolamine derivatives and their pharmaceutically acceptable acid addition salts having anti-histaminic properties, compositions containing the same, and methods of treating allergic diseases in warm-blooded animals.

  小说N-(4-哌啶基)双环缩合2-咪唑胺衍生物及其药学上可接受的酸盐，具有抗组胺作用的组合物，以及治疗温血动物过敏性疾病的方法。
• 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS
  申请人：Taveras Arthur G.

  公开号：US20090306079A1

  公开（公告）日：2009-12-10

  There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

  公开了以下式子的化合物，或其药学上可接受的盐或溶剂，其对于化学因子介导的疾病如急慢性炎症性疾病和癌症的治疗是有用的。